MD FRACP FACP FACCP FBPhS
A renowned clinician-scientist, Professor Albert Frauman’s research has focused on autoimmunity, viral infection and biomarkers of cancer progression. Now Director and CEO of Esfam Biotech, he has a long-standing interest in biomarkers as diagnostics and drug targets, and experience in the design, conduct and analysis of Phase I, II and III studies.
Professor Frauman is trained in Clinical Pharmacology and Endocrinology and completed his research doctorate at the University of Melbourne, where he researched the pharmacokinetics of alternative insulin formulations in diabetes. He later completed postdoctoral research on the cell and molecular biology of the thyroid at Harvard Medical School and the Walter and Eliza Hall Institute.
With over 70 peer-reviewed research publications, Professor Frauman ’s career highlights include serving as Medical Director of a phase 1 clinical trials facility, Nucleus Network and investigator on large Program Grants from the Victorian Government, Victoria Cancer Agency and Australian Cancer Research Foundation. He has been a Professorial Fellow at the Baker IDI Institute and a member of the Editorial Boards for the British Journal of Clinical Pharmacology, American Journal of Pharmacogenomics, Molecular Diagnosis and Therapy, and the Oncology Times.